Loading...
•
Dec 31, 2024
Paysign Q4 2024 Earnings Report
Paysign reported solid Q4 2024 results with a 14% revenue increase, strong growth in patient affordability revenue, and a slight decline in plasma revenue.
Key Takeaways
Paysign's Q4 2024 performance featured double-digit revenue growth driven by significant expansion in the patient affordability segment, while plasma revenue softened due to market normalization. The company posted $1.37 million in net income and ended the quarter with $10.77 million in cash.
Total Q4 2024 revenue was $15.61 million, up 14% year-over-year.
Net income for the quarter reached $1.37 million with diluted EPS of $0.02.
Patient affordability revenue surged by 156.5% to $4.31 million.
Plasma revenue declined 6.2% to $10.80 million due to normalized inventory levels.
Revenue by Segment
Forward Guidance
Paysign anticipates continued growth in 2025, driven by patient affordability revenue, while plasma revenue is expected to moderate. Full-year revenue is projected between $68.5 million and $70.0 million, with pharma revenue doubling year-over-year.
Positive Outlook
- Pharma revenue expected to grow at least 100% in 2025.
- Plasma revenue to make up approximately 57.5% of total revenue.
- Continued strength in patient affordability business with increasing contribution to revenue.
- Anticipated full-year gross profit margins of 62%-64%.
- Expected adjusted EBITDA in the range of $12.5 to $13.5 million for full-year 2025.
Challenges Ahead
- Near-term slowdown in plasma business due to industry oversupply.
- Plasma revenue expected to decline year-over-year in early 2025.
- Operating expenses projected to increase due to acquisitions and hiring.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...